Current guidelines for cervical cancer screening

Reading File

Finding Sources

Reading File

I now have sufficient information to provide a comprehensive, well-cited response on cervical cancer screening guidelines.

Cervical Cancer Screening Guidelines

When to Start Screening

Screening begins at age 21, regardless of the age of sexual debut. This reflects the very low prevalence of invasive cervical cancer in adolescents, the slow multiyear course of cervical carcinogenesis, and the real (if small) risk of preterm birth associated with excisional procedures performed unnecessarily in young women. — Berek & Novak's Gynecology

Screening Intervals by Age Group

Age Group	Recommended Test	Interval
21–29 years	Pap smear (cytology) alone	Every 3 years
30–65 years	Pap smear alone	Every 3 years
30–65 years	Pap + HPV co-testing	Every 5 years (preferred by USPSTF 2017)
30–65 years	HPV test alone (primary HPV screening)	Every 5 years (USPSTF 2017)

HPV DNA testing is not recommended under age 30 because of the high prevalence of transient HPV infection in younger women, making the test poorly specific in that age group. — Robbins, Cotran & Kumar Pathologic Basis of Disease

Special Populations (More Frequent Screening)

The following groups require more intensive surveillance:

HIV-positive women: Pap twice in the first year, then annually
Immunosuppressed individuals (e.g., transplant recipients, long-term corticosteroids)
DES (diethylstilbestrol) daughters
History of CIN 2+ or cervical cancer: Annual screening for 20 years

— Berek & Novak's Gynecology

When to Stop Screening

Ages 65–70: Discontinuation is reasonable if there is an adequate prior screening history (typically 3 consecutive negative Pap smears or 2 consecutive negative co-tests within the prior 10 years, with the most recent within 5 years)
Annual reassessment of risk factors is still appropriate after stopping
Post-hysterectomy for benign indications: Screening can be discontinued if there is no prior history of high-grade CIN or cervical cancer — Berek & Novak's Gynecology

HPV Testing Details

Test	FDA Approval
Hybrid Capture 2	ASC-US triage, Co-test
Cobas HPV (L1 DNA, PCR)	ASC-US triage, Co-test, Primary HPV screening
APTIMA (E6/E7 mRNA)	ASC-US triage, Co-test, reflex typing for 16/18/45
Cervista	ASC-US triage, Co-test

— Berek & Novak's Gynecology, Table 16-2

Management of Abnormal Results

ASC-US: Reflex HPV testing; if HPV positive → colposcopy
LSIL: Colposcopic examination; confirmed LSIL can be managed conservatively (watchful waiting) or ablated (cryotherapy) depending on follow-up reliability
HSIL: Cervical conization (superficial excision) is the standard treatment
HPV positive, cytology normal (in women ≥30): Repeat cytology every 6–12 months — Robbins, Cotran & Kumar

The Pap Smear — Cytologic Spectrum

The transformation zone is circumferentially scraped; cells are fixed and stained using the Papanicolaou method. The cytologic spectrum from normal to HSIL reflects a progressive reduction in cytoplasm and increase in the nucleus-to-cytoplasm ratio as differentiation is lost.

Cervical cytology from normal to HSIL on Pap smear

Cervical cytology spectrum: (A) Normal squamous cells; (B) LSIL (koilocytes); (C–D) HSIL — note rising nucleus-to-cytoplasm ratio. — Robbins, Cotran & Kumar, Fig. 22.18

Prevention: HPV Vaccination

Vaccination against oncogenic (and low-risk) HPV types is recommended for:

All children and adults ages 9–26 years
Selected adults 27–45 years (shared decision-making based on risk)

— Robbins, Cotran & Kumar Pathologic Basis of Disease

Key takeaway: The USPSTF 2017 and ACS guidelines converge on starting at age 21, using cytology alone every 3 years for ages 21–29, and offering cytology + HPV co-testing or primary HPV testing every 5 years for ages 30–65. Routine annual Pap smears are no longer recommended for average-risk women. Always individualize based on risk factors and immunocompromise status.

Carcinoma lung nsccl latest update as per nccn

Reading File

Finding Sources

Reading File

Loading Image

I now have comprehensive, current data from Harrison's 2025, Murray & Nadel's, and Fishman's. Here is a detailed synthesis aligned with current NCCN-concordant guidelines:

Non-Small Cell Lung Cancer (NSCLC) — Current Management Guidelines

Important note: The library contains authoritative medical textbooks (Harrison's 2025, Murray & Nadel's, Fishman's). The NCCN guidelines themselves are a proprietary online resource updated continuously; the principles below are concordant with the most current NCCN framework as reflected in these texts.

Overview

NSCLC accounts for ~85% of all lung cancers and includes:

Adenocarcinoma (most common)
Squamous cell carcinoma
Large cell carcinoma

5-year survival for NSCLC is ~23%, reflecting the fact that the majority present at advanced stages. — Murray & Nadel's Textbook of Respiratory Medicine

Staging-Based Treatment Framework

Stage	General Strategy
Stage I	Surgery alone
Stage II	Surgery + adjuvant chemotherapy
Stage IIIA (resectable)	Multimodality: chemo + surgery ± immunotherapy
Stage IIIA/B (unresectable)	Concurrent chemoradiotherapy → consolidation immunotherapy (durvalumab)
Stage IV (metastatic)	Systemic therapy: targeted or immunotherapy ± chemotherapy

— Murray & Nadel's Textbook of Respiratory Medicine

Early-Stage NSCLC (Stages I–III): Perioperative Advances

A major paradigm shift has occurred — targeted therapy and immunotherapy are now incorporated into curative-intent treatment:

Trial	Stage	Regimen	Key Result
CheckMate 816 (Neoadjuvant)	IB–IIIA	Nivolumab + chemo × 3 cycles	EFS HR 0.63, p=.005
KEYNOTE-671 (Perioperative)	II–IIIB (N2)	Pembrolizumab + chemo → surgery → pembrolizumab ~9 mo	EFS HR 0.58; OS HR 0.72
IMPower010 (Adjuvant)	II–IIIA, PD-L1 ≥1%	Chemo → atezolizumab × 1 year	DFS HR 0.66
KEYNOTE-091/PEARLS (Adjuvant)	IB–IIIA	Chemo → pembrolizumab × 1 year	DFS HR 0.73
ADAURA (Adjuvant)	IB–IIIA, EGFR mut+	Osimertinib × 3 years	DFS HR 0.20; OS HR 0.49
ALINA (Adjuvant)	IB–IIIA, ALK fusion+	Alectinib × 2 years	DFS HR 0.24

— Harrison's Principles of Internal Medicine 22E (2025)

Mandatory Molecular Testing for All Advanced NSCLC

All patients with stage IV NSCLC must undergo comprehensive molecular profiling before initiating therapy. Actionable targets and approved agents:

Targeted therapy options by driver mutation in metastatic NSCLC

Targeted therapy options by driver mutation — Harrison's 2025, Fig. 83

Driver Alteration	Approved Targeted Agents
EGFR exon 19 del / L858R	Osimertinib (preferred 1st line), Afatinib, Dacomitinib, Erlotinib ± ramucirumab/bevacizumab, Gefitinib
EGFR exon 20 insertion	Amivantamab + carboplatin/pemetrexed
ALK fusion	Alectinib, Brigatinib, Lorlatinib, Ceritinib, Crizotinib
KRAS G12C	Adagrasib, Sotorasib (*2nd line)
ERBB2 (HER2) mutation	Fam-trastuzumab deruxtecan-nxki, Ado-trastuzumab emtansine
ROS1 fusion	Crizotinib, Entrectinib, Repotrectinib, (Ceritinib), (Lorlatinib)
RET fusion	Pralsetinib, Selpercatinib
MET exon 14 skipping	Capmatinib, Crizotinib, Tepotinib
BRAF V600E	Dabrafenib/Trametinib, Encorafenib/Binimetinib, Vemurafenib
NTRK 1/2/3 fusion	Entrectinib, Larotrectinib
Atypical EGFR (G719X, L861Q, S768I)	Afatinib

Key rule: Patients with EGFR or ALK driver mutations derive greater benefit from TKIs than immunotherapy, even when PD-L1 is ≥50% — they should receive a TKI first, not immunotherapy. — Harrison's 2025

Stage IV NSCLC Without Actionable Mutations: Immunotherapy Framework

Treatment is guided by histology and PD-L1 expression:

First-line treatment by PD-L1 status and histology in metastatic NSCLC

First-line therapy algorithm for stage IV, driver-negative NSCLC — Harrison's 2025, Fig. 83

PD-L1 ≥50% (no driver mutation):

Pembrolizumab monotherapy (KEYNOTE-024, KEYNOTE-042): preferred 1st-line
Atezolizumab monotherapy (IMpower 110): alternative
Nivolumab + ipilimumab (CheckMate 227): option
Chemo + immunotherapy also acceptable

PD-L1 1–49% (no driver mutation):

Chemo + immunotherapy preferred (monotherapy less supported)
Anti-PD-1 + anti-CTLA-4 ± chemo

PD-L1 <1% or PD-L1 low:

Chemo + immunotherapy combination
Anti-PD-1 + Anti-CTLA-4 + chemo

Histology-specific chemotherapy backbone:

Nonsquamous (adenocarcinoma): Cisplatin + pemetrexed (superior to gemcitabine; pemetrexed restricted to nonsquamous due to thymidylate synthase expression)
Squamous: Cisplatin + gemcitabine (preferred)
Bevacizumab (anti-VEGF): add to platinum + paclitaxel for nonsquamous only (contraindicated in squamous — hemorrhage risk)

— Murray & Nadel's; Harrison's 2025

Stage III Unresectable: Chemoradiotherapy + Durvalumab

Concurrent platinum-based chemoradiotherapy followed by consolidation durvalumab (anti-PD-L1) for up to 12 months is the standard of care for unresectable stage III NSCLC with PS 0–1 after chemoRT (PACIFIC trial). Immunotherapy also shows promise in early-stage disease. — Murray & Nadel's

Maintenance Therapy (Stage IV, Nonsquamous, Good PS)

After 4–6 cycles of platinum doublet + immunotherapy, in patients with stable/responding disease:

Pemetrexed maintenance: 22% reduction in risk of death vs. placebo
Bevacizumab maintenance: improved PFS (4.4 vs. 2.8 mo) and OS
Continuation immunotherapy per initial regimen

Second-Line and Beyond

Docetaxel ± ramucirumab (all histologies): standard after progression on platinum-based therapy; ramucirumab (anti-VEGFR2) improves PFS and OS
Pemetrexed (2nd line, nonsquamous only)
Afatinib (2nd line, squamous)
Erlotinib: option in patients unsuitable for immunotherapy or chemo (OS 6.7 vs. 4.7 mo vs. placebo)
Immunotherapy agents approved 2nd-line: nivolumab, pembrolizumab, atezolizumab

Key Summary Points

Molecular testing is mandatory for all advanced NSCLC before any treatment decision
Driver mutation present → targeted TKI first (not immunotherapy, even if PD-L1 high)
Driver mutation absent, PD-L1 ≥50% → immunotherapy monotherapy (pembrolizumab)
Driver mutation absent, PD-L1 <50% → chemo + immunotherapy combination
Early-stage: perioperative immunotherapy (nivolumab/pembrolizumab) and adjuvant targeted therapy (osimertinib for EGFR+; alectinib for ALK+) are now standard
Histology matters: pemetrexed for nonsquamous; gemcitabine for squamous
Chemotherapy backbone: cisplatin or carboplatin-based doublets remain the foundation when combined with immunotherapy

— Harrison's Principles of Internal Medicine 22E (2025); Murray & Nadel's Textbook of Respiratory Medicine; Fishman's Pulmonary Diseases and Disorders

This is a shared conversation. Sign in to Orris to start your own chat.